Cleerly ISCHEMIA vs FEops HEARTguideTM
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if you need a non-invasive, AI-powered assessment of coronary artery disease to determine the likelihood of ischemia and characterize plaque burden from CCTA scans. This tool is ideal for physicians seeking to personalize diagnosis and treatment plans for patients with suspected or known heart disease, prior to considering invasive procedures.
View Cleerly ISCHEMIA →Choose FEops HEARTguideTM if…
Choose FEops HEARTguideTM if you require advanced, AI-based predictive simulations and anatomical insights for planning structural heart interventions like TAVI or LAAO. This platform is best suited for optimizing device sizing and positioning, ensuring precise pre-procedural planning to enhance procedural success and patient outcomes.
View FEops HEARTguideTM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | FEops HEARTguideTM |
|---|---|---|
| Pricing | Contact for details | Contact for pricing |
| Deployment | Web-based platform; data transfer via Cleerly Proxy (VPN or virtual appliance) | Cloud-based |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FEops HEARTguideTMFEops HEARTguideTM offers an intuitive cloud-based platform with interactive 2D and 3D viewers, semi-automatic and manual measurement options, and a DICOM interface for seamless workflow integration. Its demonstrated ability to save significant time in analysis and its collaborative features provide a slight edge in user experience over Cleerly ISCHEMIA's web-based reports and PowerScribe integration.
Clinical Value
TieBoth tools offer substantial clinical value in distinct areas of cardiology, backed by robust clinical trials. Cleerly ISCHEMIA provides highly accurate non-invasive ischemia detection and prognostic risk stratification for coronary artery disease. FEops HEARTguideTM significantly improves procedural efficiency and outcomes for complex structural heart interventions like TAVI and LAAO through predictive simulations.
Pricing & Value
Cleerly ISCHEMIAWhile both tools require direct contact for pricing, Cleerly ISCHEMIA offers greater transparency regarding reimbursement. It is billable using established Category I CPT codes (75580 and 75577 for 2026) and is covered by Medicare and most U.S. commercial payers, reducing financial uncertainty for providers. FEops HEARTguideTM's pricing model and reimbursement pathways are not publicly disclosed.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and offering BAAs. Cleerly ISCHEMIA provides secure data transfer via Cleerly Proxy (VPN or virtual appliance) and API integration with PowerScribe. FEops HEARTguideTM features a cloud-based platform with DICOM integration, secure collaborative features, and multi-factor authentication, making both well-suited for healthcare enterprise environments.
Innovation
FEops HEARTguideTMBoth tools are highly innovative. Cleerly ISCHEMIA advances non-invasive coronary artery disease diagnosis with AI-driven FFR estimation and detailed plaque characterization. However, FEops HEARTguideTM's application of 'digital twin' technology for predictive simulations in complex structural heart procedure planning, allowing virtual device testing and optimization, represents a slightly more groundbreaking approach to personalized intervention.
Support & Docs
FEops HEARTguideTMFEops HEARTguideTM explicitly provides a dedicated support email address ([email protected]) and mentions a 'Documentation' page accessible to logged-in users, indicating clear channels for assistance and resources. Cleerly ISCHEMIA does not provide similar explicit details regarding customer support or documentation in the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | FEops HEARTguideTM |
|---|---|---|
| Primary Function | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO. |
| Target Medical Specialties | Cardiology, Radiology | Cardiology, Cardiothoracic Surgery, Radiology |
| Input Scan Type | CCTA scans | CT scans |
| Core AI Analysis Capabilities | AI-enabled CCTA analysis, Non-invasive fractional flow reserve (FFR) estimation, Vessel-level ischemia likelihood determination, Coronary plaque characterization (volume, type, location), Stenosis severity assessment | Predictive simulation technology for device-anatomy interaction, AI-based anatomical measurements from CT scans |
| Key Output/Visualization | 3D digital models of coronary arteries, Comprehensive interactive web-based reports | Interactive 2D and 3D viewer for detailed analysis, Segmentation of cardiovascular structures, Visualization and image reconstruction techniques (2D review, MPR) |
| Integration Capability | Integration with PowerScribe via API | DICOM interface for easy integration into clinical workflow |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and FEops HEARTguideTM.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or FEops HEARTguideTM
Backers
Who funded each tool's parent company.